What Promazin Jelfa treats: Main Uses and Benefits

Promazin Jelfa is utilized for its sedative and stabilizing properties in acute clinical situations.

This medication is relevant across therapeutic domains where additional symptomatic support is used to manage intense manifestations, such as acute behavioral stabilization and the supportive management of psychotic or manic symptoms. In a separate application, it is also used to provide supportive antiemetic action against persistent and severe emesis.

The primary application involves addressing symptom clusters that may become intense or disruptive, such as severe restlessness, psychomotor agitation, marked emotional distress, and uncontrolled vomiting. This supportive role is intended to assist with easing discomfort during periods of heightened symptoms and helps with maintaining functional stability.

---

Quick Fact: Relevant for Severe Agitation Promazin Jelfa is applied for short-term symptomatic management to assist with acute, severe restlessness and volatility associated with psychiatric crises.

Eligibility for Promazin Jelfa

Official regulatory documentation defines clear criteria for who must not use Promazin Jelfa and for whom use is significantly restricted.

---

Populations For Whom Use Is Contraindicated (Prohibited)

Classification	Exclusion Criteria (Must Not Use)
Hypersensitivity	Known allergy to Promazine, other phenothiazine derivatives, or any product component.
Clinical Status	Comatose state, severe circulatory failure, or recent large intake of CNS depressants (e.g., heavy alcohol use or certain narcotic drugs).
Organ/Blood Disease	Severe liver or kidney failure, agranulocytosis (lack of granulocytes), or pheochromocytoma.
Neurological Disease	Parkinson's disease or a history of malignant neuroleptic syndrome.
Age	Children (the medicine is generally not approved for use in this population).
Pregnancy/Lactation	First three months of pregnancy and during breastfeeding.

---

Populations Requiring Caution or Special Consideration

Use is restricted or requires caution in patients with less severe hepatic or renal impairment, history of extrapyramidal disorders, narrow-angle glaucoma, prostatic hyperplasia, heart disease (including arrhythmias or conditions predisposing to cardiac arrhythmias), or chronic respiratory disorders like asthma. Older adults require careful monitoring due to increased risks of side effects such as extrapyramidal disorders.

Promazin Jelfa (Promazine hydrochloride) interacts with numerous other medicinal products and substances, primarily due to additive effects on the central nervous system (CNS) and potential cardiac risk, as documented in official regulatory labeling.

Formal Interaction Restrictions

Co-administration with drugs known to prolong the QT interval is not recommended. This is due to a pharmacodynamic interaction that increases the risk of ventricular arrhythmias, including Torsade de Pointes. Examples include certain Class IA and Class III antiarrhythmics, some antimicrobials (e.g., erythromycin IV), and tricyclic antidepressants.

Documented Interaction Patterns

Interaction Type	Interacting Medicines/Substances	Regulatory Statement
Pharmacodynamic Synergism	CNS depressants (including alcohol, opioids, anxiolytics)	May result in the accentuation of their sedative and hypotensive effects.
Pharmacodynamic Toxicity	Lithium, Metoclopramide, Tetrabenazine, Tramadol	Increased risk of extrapyramidal effects or convulsions.
Pharmacokinetic (Exposure)	Ritonavir, Cimetidine	May cause an increase in plasma concentration of Promazine or enhance its effects.
Pharmacokinetic (Absorption)	Antacids, Kaolin	May result in reduced absorption of Promazine, potentially lowering its presence in the body.

Antihypertensive drugs may exhibit an enhanced hypotensive effect when co-administered. The efficacy of dopaminergic drugs and the hypoglycaemic effect of sulfonylureas may be antagonized by Promazine.

The mechanism of action for Promazin Jelfa centers on its function as a non-selective antagonist across several neurotransmitter receptor systems in the central nervous system (CNS) and periphery. By blocking these receptors, the drug rapidly reduces signal transduction within these pathways.

---

Blocking Neurotransmitter Receptors ( D2, H1, 5-HT2 A)

Promazin is an antagonist at dopamine D2, histamine H1, and serotonin 5-HT2 A receptors. This wide-ranging antagonism interrupts neurotransmitter signaling at these sites, particularly in the brain's mesolimbic pathway and the chemoreceptor trigger zone (CTZ).

---

Modulating Central Arousal and Autonomic Tone

Histamine H1 and muscarinic receptor blockade causes central nervous system depression via modulation of arousal pathways. Additionally, antagonism of peripheral mathbfalpha1 adrenergic receptors modulates the autonomic nervous system, reducing sympathetic outflow and peripheral vasoconstriction to effect a change in vascular tone.

Official Administration Guidelines for Promazin Jelfa

Promazin Jelfa (promazine hydrochloride) is administered according to clinical guidelines. The medicine is available for oral (PO) administration as a syrup or tablet, and for parenteral administration as an injection.

Parameter	Official Instruction
Route of Administration	Oral (syrup or tablets) or Deep Intramuscular (IM) injection
Initial Dosing	Treatment typically commences with a low initial dosage. Dosing is gradually increased at frequent, regular intervals under medical supervision to achieve the desired response.
Adult Dosing (Oral)	Typically 100 mg to 200 mg, up to four times daily, with a maximum daily dose not exceeding 1000 mg
Elderly Dosing	Treatment typically starts with a lower dose, usually 25 mg initially, up to 50 mg four times daily. The lowest effective dose for the shortest period possible is utilized.
Pediatric Use	Promazin Jelfa is not recommended for use in children
Discontinuation	The medicine is typically gradually withdrawn (tapered) to prevent the occurrence of acute withdrawal symptoms

Dosage intervals are usually six to eight hours, though some patients may be maintained on a single bedtime dose. The administration route and regimen is determined by a healthcare professional based on the specific formulation and patient needs.

Promazin Jelfa: Overview of Studies

Evidence for Use in Acute Agitation and Disturbed Behavior

Promazin Jelfa was evaluated in research exploring situations where individuals experience acute psychomotor agitation or highly disturbed behavior. The evidence includes structures such as randomized controlled trials (RCTs), systematic reviews, and observational settings focused on immediate care. These studies were applied in populations of adults presenting with conditions associated with acute or disruptive episodes.

The research examined measurements related to observed changes in behavior and the time intervals monitored. Findings describe patterns observed in the studies related to measured changes in episodic or acute symptoms, often over short intervals.

Long-term outcomes are not well characterized for this application, as follow-up durations were limited. Furthermore, many existing studies are older, and large-scale, recent placebo-controlled trials are limited.

Evidence for Use in Severe Nausea and Vomiting (Antiemetic Action)

Promazin Jelfa was included in research protocols examining conditions involving periods of heightened symptoms, specifically severe nausea and vomiting. The evidence available includes historical clinical trials and some comparative studies. The research examined outcomes linked to inflammatory or irritative states, focusing on measurements of changes in the number of vomiting episodes or subjective symptom scores.

Comparative evidence is lacking, and evidence quality varies across studies, as much of the data are historical. This research contributes to understanding what has been observed so far but provides limited information for long-term outcomes related to this specific application.

What Is Still Uncertain About Promazin Jelfa Research

Across all indications, research exploring the outcomes related to Promazin Jelfa has generally focused on short-term or episodic symptom patterns. The existing evidence base contains studies that are generally older and may have modest sample sizes. This means that the findings describe patterns observed in the studied populations but do not determine whether an individual will respond similarly. Comparative evidence against many newer treatments remains lacking.

Key Studies & References

1. Study protocol for a randomised controlled trial of haloperidol plus promethazine plus chlorpromazine versus haloperidol plus promethazine for rapid tranquilisation for agitated psychiatric patients in the emergency setting (TREC-Lebanon)
2. PRESCRIBING INFORMATION PERPHENAZINE (General Phenothiazine Warnings and Safety in the Elderly)

Common questions about Promazin Jelfa (FAQ)

Q: How long does the effect of a single dose of Promazin Jelfa typically last?

Official information indicates that the recommended dosing interval for Promazin is typically six to eight hours. Some individuals may be maintained on a single daily dose, often taken at bedtime. The recommended dosing intervals provide an indication of the timeframe the medicine is intended to cover.

---

Q: Does Promazin Jelfa interfere with hormonal balance or cause changes like galactorrhea?

Antipsychotic drugs in this class may lead to an increase in the hormone prolactin. This hormonal change can be associated with side effects such as breast enlargement and the abnormal production of breast milk, which is known as galactorrhea. Any changes related to hormonal balance should be discussed with a healthcare professional.

---

Q: Is Promazin Jelfa generally appropriate for use in patients with non-severe kidney problems?

Official prescribing information states that Promazin Jelfa should be used with caution if an individual has renal (kidney) failure. The medicine is, however, contraindicated (prohibited) for use in patients with severe kidney failure.

---

Q: What are some less common but serious side effects of Promazin Jelfa that require immediate attention?

Serious reactions that require immediate medical attention are rare but include a potentially fatal condition called Neuroleptic Malignant Syndrome (NMS), which involves high fever and muscle rigidity. Other serious concerns are severe blood disorders like agranulocytosis, and serious ventricular arrhythmias (abnormal heart rhythms) that are associated with significant risk.

---

Q: How does Promazin Jelfa influence the body's temperature regulation?

Regulatory documents indicate that phenothiazine medications, the class to which Promazin belongs, may impair the body's natural ability to regulate its temperature. Due to this impairment, there is an increased need for caution in extreme temperature environments.

---

Q: Does Promazin Jelfa interact with any herbal products, such as St. John's Wort?

Promazin is known to interact with various medicinal and herbal products. The official information advises special consideration regarding the co-administration of Promazin with certain herbal products due to the potential for interactions.

---

Q: What is the mechanism by which Promazin Jelfa exhibits its weak anti-vomiting effect?

The medicine works by acting as an antagonist (blocker) at various receptors in the central nervous system. This includes activity in the brain's chemoreceptor trigger zone, which is the area responsible for initiating vomiting. This blocking action contributes to the medicine's utility in treating severe nausea and vomiting.

---

Q: Can Promazin Jelfa worsen pre-existing glaucoma or prostatic hypertrophy symptoms?

Official safety information indicates that Promazin Jelfa requires caution for use in patients with narrow-angle glaucoma or prostatic hypertrophy (enlarged prostate). These conditions are specifically listed as requiring special consideration for use.

---

Q: Why must Promazin Jelfa be used cautiously in patients with severe respiratory issues like asthma?

The regulatory documents advise caution for the use of Promazin in patients with severe respiratory diseases, such as asthma or other chronic lung issues. This is because official sources state that the medication carries a risk of respiratory depression (slowed or ineffective breathing).

---

Q: Is the potential for seizures increased by taking Promazin Jelfa?

The regulatory information indicates that caution is advised for patients who have epilepsy or other conditions that predispose them to seizures. This is due to the potential for Promazin Jelfa to lower the seizure threshold.

---

Q: Is Promazin Jelfa widely used outside of the treatment of psychomotor agitation?

While Promazin is commonly known for treating acute psychomotor agitation, official indications confirm that it is also used for the relief of severe nausea and vomiting. The fact that it is indicated for two conditions suggests its utility beyond psychomotor agitation.

---

Q: Are there any known issues with fertility or sexual function linked to Promazin Jelfa use?

Phenothiazines like Promazin can increase the hormone prolactin. This increase may be associated with side effects related to reproductive health, including changes in libido or other aspects of sexual function.

Promazin Jelfa must be stored strictly according to official regulatory requirements to ensure its stability.

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store below 25 C (Maximum 77°F).
Protection	Must be protected from light and kept in the original packaging.
Accessibility	The medicine must be kept out of the sight and reach of children.
Prohibited	Avoid temperatures exceeding 25 C.

Disposal Instructions

To dispose of unused or expired Promazin Jelfa, the official guidance is to use a medicine take-back program or permanent collection site, which is the preferred method.

If a take-back option is not available, the medication must be disposed of in the household trash. This procedure involves mixing the medicine with an unappealing substance, such as used coffee grounds or dirt, placing the mixture in a sealed container, and then discarding it. The medicine must not be disposed of by flushing down the toilet or pouring down a sink.